Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval
TCR therapies are minimally engineered and can target both cell surface antigens and intracellular antigens.
TCR therapies are minimally engineered and can target both cell surface antigens and intracellular antigens.
What's Your Reaction?
